Status:
COMPLETED
Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome
Lead Sponsor:
German Institute of Human Nutrition
Collaborating Sponsors:
Danone Research Foundation
Leiber Company
Conditions:
Overweight
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Insoluble (1,3),(1,6)-beta-D-glucan from bakers yeast are indigestible polysaccharides. Previous studies indicate that the intake of insoluble dietary fiber is strongly associated with reduced risk of...
Eligibility Criteria
Inclusion
- Healthy subjects with normal glucose tolerance (NGT)
- Impaired glucose tolerance (IGT)
- Impaired fasting glucose (IFG)
Exclusion
- Any severe cardiac disease
- Liver
- Kidney diseases
- Type 1 or type 2 diabetes
- Chronical and acute inflammatory diseases
- Lipid lowering drugs
- Cortisone
- Antibiotics
- Non-steroidal antiinflammatory drugs
- Including low dose acetylsalicylic acid
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00403689
Start Date
November 1 2006
End Date
March 1 2008
Last Update
August 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
German Institute of Human Nutrition, Department of Clinical Nutrition, Potsdam-Rehbrücke
Nuthetal, Germany, 14558